<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One hundred ninety-three patients with stage II, III, or IV follicular large-cell, diffuse large-cell, diffuse mixed, <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e>, or diffuse small noncleaved-cell (non-Burkitt's) <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were randomized to receive either <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 650 mg/m2 intravenously (IV), <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> 25 mg/m2 IV, <z:chebi fb="0" ids="4911">etoposide</z:chebi> 120 mg/m2 IV on day 1, <z:chebi fb="0" ids="28925">mechlorethamine</z:chebi> 6 mg/m2 IV, <z:chebi fb="0" ids="28445">vincristine</z:chebi> 1.4 mg/m2 (no cap at 2 mg total dose) IV on day 8, <z:chebi fb="0" ids="8382">prednisone</z:chebi> 60 mg/m2 orally daily days 1 through 14, procarbazine 100 mg/m2 orally daily days 8 through 14, and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> 500 mg/m2 IV on day 15 with leucovorin 50 mg/m2 orally every 6 hours for four doses beginning 24 hours after <z:chebi fb="0" ids="44185">methotrexate</z:chebi> with cycles repeated every 28 days (ProMACE-MOPP) or same day-1 treatment as ProMACE-MOPP plus <z:chebi fb="0" ids="28680">cytarabine</z:chebi> 300 mg/m2 IV, <z:chebi fb="0" ids="3139">bleomycin</z:chebi> 5 U/m2 IV, <z:chebi fb="0" ids="28445">vincristine</z:chebi> 1.4 mg/m2 (no cap at 2 mg total dose) IV, and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> 120 mg/m2 IV on day 8, leucovorin 25 mg/m2 orally every 6 hours for four doses beginning 24 hours after <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> 60 mg/m2 orally daily days 1 through 14 with cycles repeated every 21 days (ProMACE-CytaBOM) </plain></SENT>
<SENT sid="1" pm="."><plain>Co-trimoxazole two double-strength tablets orally twice daily throughout the period of treatment was added to the ProMACE-CytaBOM regimen when an increased risk of Pneumocystis carinii <z:hpo ids='HP_0002090'>pneumonia</z:hpo> was found in the first 35 patients receiving this combination </plain></SENT>
<SENT sid="2" pm="."><plain>Median follow-up is 5 years </plain></SENT>
<SENT sid="3" pm="."><plain>Among the 99 patients treated with ProMACE-MOPP, 73 achieved a complete remission (CR) (74%), 30 complete responders have relapsed (41%), and 45 patients have died (45%), including two (2%) of treatment-related causes </plain></SENT>
<SENT sid="4" pm="."><plain>Among the 94 patients treated with ProMACE-CytaBOM, 81 achieved a CR (86%), 22 complete responders have relapsed (27%), and 31 patients have died (33%) </plain></SENT>
<SENT sid="5" pm="."><plain>The complete response rate (P2 = .048) and survival (P2 = .046) were significantly higher for patients treated with ProMACE-CytaBOM </plain></SENT>
<SENT sid="6" pm="."><plain>The mortality of ProMACE-CytaBOM treatment overall was six of 94 patients (6.4%) </plain></SENT>
<SENT sid="7" pm="."><plain>There was no treatment-related mortality among patients treated with prophylactic co-trimoxazole (n = 59) </plain></SENT>
<SENT sid="8" pm="."><plain>ProMACE-CytaBOM combination chemotherapy with co-trimoxazole prophylaxis is a safe and effective treatment for patients with aggressive histology malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and is superior to ProMACE-MOPP </plain></SENT>
</text></document>